Who is eligible for a booster and additional dose of the COVID-19 vaccine?
The Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC) have authorized a bivalent booster of the Pfizer COVID-19 vaccine for all individuals 5 years of age and older, two months after the last dose in the initial series or after the last monovalent booster shot.
The FDA and CDC have also authorized a bivalent booster of the Moderna COVID-19 vaccine for all individuals 6 years of age and older, two months after the last dose in the initial series or after the last monovalent booster shot.
Moderately and severely immunocompromised individuals:
- Immunocompromised individuals ages 5 and older who received Moderna or Pfizer should receive a third dose as part of the primary series at least 28 days later and then a bivalent booster two months later.
Moderate or severely immunocompromised is defined as the following:
- Active treatment for solid tumor and hematologic malignancies
- Receipt of solid-organ transplant and taking immunosuppressive therapy
- Receipt of CAR-T-cell or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppression therapy)
- Moderate or severe primary immunodeficiency (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome)
- Advanced or untreated HIV infection
- Active treatment with high-dose corticosteroids (i.e., ≥20mg prednisone or equivalent per day), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, tumor-necrosis (“TNF”) blockers, and other biologic agents that are immunosuppressive or immunomodulatory
- Any other moderately to severely immunocompromising condition deemed as such by the treating provider
Of important note: The FDA and CDC also confirmed that eligible individuals can receive a different COVID-19 vaccine as a booster from the one they initially received.
We continue to monitor for new developments and will provide updates if a booster is recommended for additional populations.
For more information, view our vaccine resource guide or visit the CDC.